Monday, September 13, 1993
Improving on a blockbuster
In the search for sustainable business models, many biotech companies can expect to
find themselves butting up against rival technologies in therapeutically similar markets.
In these instances, finding clinical advantage in a subset of the target market may be
On the other hand, finding defensible ways to add value in terms of price or an
improved clinical profile could be the route to a defensible